Substitute for PTO-1390 (Rev. 07-2005) "  Approved for use through 3/31/2007. OM	Fransmittal Letter to the United States Designated Elect MB 0651-0021	ACCUPITY STORY						
. → U.S. PAT	ENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER						
U.S.	. DEPARTMENT OF COMMERCE	21592YP						
	TO THE UNITED STATES	ILS AHPLICATION DOCALITATION, see 37 CFR 1.5)						
DESIGNATED/ELECTE CONCERNING A FILIN	U.S. A. F. L. J. A. D. C. S.							
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/US2004/042173	15 December 2004	19 December 2003						
DISEASE	IDE BETA-SECRETASE INHIBITO	ORS FOR THE TREATMENT OF ALZHEIMER'S						
Matthew G. Stanton		el, Shaun R. Stauffer, Linghang Zhang, Jennifer R. Davis and						
Applicant herewith submits to the other information:	United States Designated/Elected Of	ffice (DO/EO/US) the following items and						
1. X This is a FIRST submission	of items concerning a filing under 35 U	U.S.C. 371.						
2.  This is a <b>SECOND</b> or <b>SUBS</b>	SEQUENT submission of items concer	rning a filing under 35 U.S.C. 371.						
	This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.							
4. X The US has been elected (PC	CT Article 31).							
5. A copy of the International A	Application as filed [35 U.S.C. 371(c)(2	2)]						
a. is attached hereto (req	quired only if not communicated by the	: International Bureau).						
b. has been communicate	ted by the International Bureau.							
c. X is not required, as the	application was filed in the United Sta	ites Receiving Office (RO/US).						
	tion of the International Application as	filed [35 U.S.C. 371(c)(2)].						
a. is attached hereto	1 14-43-25 II C C 154(4)(4)							
	ubmitted under 35 U.S.C. 154(d)(4).	OCT Aminto 10 [25 H C C 271(a)(2)]						
a. are attached hereto (re	of the International Application under P equired only if not communicated by the							
	c. have not been made; however, the time limit for making such amendments has NOT expired.							
d. have not been made an								
8. An English language translat	An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].							
9. An oath or declaration of the	An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].							
Article 36 [35 U.S.C. 371(c)	(5)].	Preliminary Examination Report under PCT						
	document(s) or information include							
	Statement under 37 CFR 1.97 and 1.98.							
12. An assignment document for is included.	recording. A separate cover sheet in c	compliance with 37 CFR 3.28 and 3.31						
13. A preliminary amendment.								
14. An Application Data Sheet u	nder 37 CFR 1.76.							
15. A substitute specification.								
16. A power of attorney and/or cl	hange of address letter.							
17. A computer-readable form of	7. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).								
19. A second copy of the English	a language translation of the internation	nal application under 35 U.S.C.154(d)(4).						
20. Other items or information:								

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"

'Astronoved for use through 3/31/2007. OMB 0651-0021

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)			INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER			
10/582856		PCT/US2004/042173			21592YP				
The following fees are submitted:						CALCULATIONS	PTO USE ONLY		
21. X Basic national fee			\$300			\$300.00			
		37 CFR 1.49							
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)							¢n.		
								\$0.00	
23. X Search fee	(37 CFI	R 1.492(b))							
					inary examination report prep				
					33(1)-(4)ional application to the USPT				
International Searchin	g Autho	rity						\$0.00	
					US and provided to the Office		\$400		
, ,		-							
					TOTAL OF	21, 22	and 23=	\$300.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of									
paper or fraction			Number	of each :	additional 50 or fraction				
Total Sheets	Extra	Sheets			to a whole number)	5.0	RATE		
121 - 100 =	21	/50	0.42	=	1	х	\$250.00	\$250.00	
_		_	th or decla	ration la	ter than 30 months from the e	arliest	claimed		
priority date [37 CFI CLAIMS	(1.492)	NUMBER	FILED		NUMBER EXTRA		RATE		
Total Claims			18	- 20 =	0	x	\$50.00	\$0.00	<u> </u>
Independent Claims			1	- 3 =	0	x	\$200.00	\$0.00	
MULTIPLE DEPENI	DENIT C	LAIM(S) (if				+	\$360.00	\$0.00	
MOETH LE DEI ENT					ATIONS (SUPTOTAL)		=	\$550.00	
						Ţ			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)].									
TOTAL NATIONAL FEE						=	\$550.00		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property.									
					TOTAL FEES ENCLO	SED	=	\$550.00	
								Amount to be	
						refunded:			
								Amount to be charged:	
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge my Deposit Account No. 13-2755 in the amount of \$550.00 to cover the above fees.									
A duplicate copy of this sheet is enclosed.  C. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any									
overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:  Customer No. 000210									
MERCK & CO., INC.									
Patent Department, RY60-30									
P.O. Box 2000 SIGNATURE									
126 East Lincoln Avenue Rahway, New Jersey 07065-0970									
John C. Todaro									
NAME DATE: June 14, 2006									
PHONE #: (732) 594-0125						<del></del>			
1 110MB#. (73	<del>_, _, _,</del>	<u></u>		_	RE	GIST	RATION NU	JMBER	<u></u>

## IAP20 Rec'd PCT/PTO 14 JUN 2006

## Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	21592YP
International Appln No.:	PCT/US2004/042173
International Filing Date:	15 December 2004
Priority Date:	19 December 2003
Title:	PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

**Inventors:** 

James C. Barrow, Craig A. Coburn, Philippe G. Nantermet, Harold G. Selnick, Shawn J. Stachel, Shaun R. Stauffer, Linghang Zhang, Jennifer R. Davis and Matthew G. Stanton

**EXPRESS MAIL CERTIFICATE** 

DATE OF DEPOSIT June 14, 2006

EXPRESS MAIL NO.

EL989585305US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O./BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

**MAILED BY**